Brief: Epigenomics: Epi ProColon(R) Test Of Choice For Millions Not Willing To Participate In Fit Or Colonoscopy Screening
10/08/2020 07:02
Aug 10 (Reuters) - EPIGENOMICS AG ECXn.DE :
* EPIGENOMICS AG - NEW STUDY PUBLISHED IN JOURNAL OF
NATIONAL
CANCER INSTITUTE CONCLUDES THAT EPI PROCOLON(R) IS TEST OF
CHOICE FOR MILLIONS OF INDIVIDUALS NOT WILLING TO PARTICIPATE IN
FIT OR COLONOSCOPY SCREENING
Source text for Eikon: ID:nEQ5p1pdGa
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns